Group One Trading’s Acumen Pharmaceuticals ABOS Stock Holding History

Group One Trading’s Portfolio ABOS Stock Details ABOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-3,900	Closed	-$6.67K	–	7991
2025 Q3	$6.67K	Buy	+3,900	New	+$5.4K	﹤0.01%	7406
2025 Q1	–	Sell	-4,700	Closed	-$8.08K	–	7481
2024 Q4	$8.08K	Sell	4,700 -16,700	-78%	-$40.2K	﹤0.01%	6205
2024 Q3	$53.1K	Sell	21,400 -36,000	-63%	-$97.7K	﹤0.01%	4624
2024 Q2	$139K	Buy	57,400 +4,700	+9%	+$15K	﹤0.01%	3693
2024 Q1	$213K	Buy	+52,700	New	+$199K	﹤0.01%	3511
2023 Q4	–	Sell	-8,600	Closed	-$35.7K	–	7277
2023 Q3	$35.7K	Buy	8,600 +4,500	+110%	+$27.8K	﹤0.01%	5403
2023 Q2	$19.7K	Buy	+4,100	New	+$19.6K	﹤0.01%	6003
2023 Q1	–	Sell	-4,500	Closed	-$24.3K	–	7109
2022 Q4	$24.3K	Sell	4,500 -11,400	-72%	-$76.6K	﹤0.01%	5483
2022 Q3	$159K	Buy	+15,900	New	+$91.2K	﹤0.01%	4357

Other funds holding ABOS

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

KIA

Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Group One Trading's ABOS Position: Q1 2026 in Review

Group One Trading reduced its Acumen Pharmaceuticals (ABOS) stake by 69% in Q1 2026, selling an estimated $8.36K and leaving 1,475 shares worth $3.48K. The position accounts for ﹤0.01% of the portfolio, ranked #6863.

Group One Trading first reported a position in ABOS in Q3 2022 and has held it in 14 quarters since. The position peaked at $304K in Q3 2024. 84 funds tracked by Wall St. Rank hold ABOS as of Q1 2026.

Group One Trading held 1,475 shares of Acumen Pharmaceuticals worth $3.48K as of Q1 2026.
Group One Trading sold 3,277 Acumen Pharmaceuticals shares in Q1 2026, an estimated $8.36K.
Acumen Pharmaceuticals made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #6863 holding.
Group One Trading first reported a position in Acumen Pharmaceuticals in Q3 2022 and has held it in 14 quarters since.
Group One Trading's Acumen Pharmaceuticals position peaked at $304K in Q3 2024.
84 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.